Perimeter Advances Surgical Technology with Completed Enrollment
Perimeter Medical Imaging AI, Inc. (TSXV: PINK) has achieved a significant milestone by completing patient enrollment in a pivotal clinical trial. This groundbreaking study is evaluating the effectiveness of the advanced Perimeter B-Series optical coherence tomography (OCT) system, which integrates artificial intelligence (AI) technology for improved margin assessment during breast-conserving surgeries (BCS).
The Importance of Margin Assessment
Breast-conserving surgery is an effective treatment option for many patients, but the challenge often lies in ensuring complete removal of cancerous tissues. Without adequate margin assessment, reoperation rates can be alarmingly high, with recent studies showing reoperation figures as high as 21.1% among commercially insured women. This low success rate underscores the urgency for improved intraoperative imaging solutions.
Perimeter's Innovative Approach
The Perimeter B-Series OCT system is poised to address this critical issue. By providing real-time visualization at the cellular level, the system aims to lower the chances of leaving malignant tissues behind. The pivotal study enrolled about 530 women aged 18 and older, all undergoing BCS for invasive ductal carcinoma or ductal carcinoma in situ, highlighting the extensive reach and potential impact of this innovation.
Details of the Pivotal Study
The randomized, double-arm clinical trial involved participants from ten different clinical sites, allowing a diverse demographic representation. Out of the approximately 530 enrolled women, about 200 will specifically assess the effectiveness of the B-Series system compared to traditional lumpectomy methods. This within-subject analysis will focus on detecting unaddressed positive margins.
Feedback from Medical Experts
Dr. Alastair Thompson, the trial's Primary Principal Investigator, expressed excitement about the timely completion of enrollment, emphasizing the importance of providing surgeons with sophisticated tools for real-time decision-making during procedures. He believes this technology has the potential to set new standards in margin assessment, offering a solution to one of the most pressing issues in surgical oncology.
Future Prospects and Expectations
With enrollment completed, all eyes are now on the forthcoming primary endpoint results of the trial, expected by the end of 2024. Should the outcomes demonstrate significant advantages, Perimeter intends to submit its findings to the U.S. Food and Drug Administration (FDA) by 2025 for authorization to market the B-Series OCT system with ImgAssist AI.
Company Overview
Perimeter Medical Imaging AI is committed to improving surgical outcomes through innovative technology. Based in Toronto and Dallas, the company focuses on transforming cancer surgery with ultra-high-resolution imaging tools. The FDA-cleared S-Series OCT system is already available in the U.S., while the next-generation B-Series OCT is making strides through its ongoing clinical trials.
Frequently Asked Questions
What is the Perimeter B-Series OCT system?
The Perimeter B-Series OCT system is an advanced imaging tool designed to assist in intraoperative margin assessment during breast-conserving surgeries.
What was the enrollment size for the pivotal trial?
The pivotal clinical trial enrolled approximately 530 women aged 18 and older undergoing breast-conserving surgeries.
What are the expected outcomes of the trial?
The primary endpoint results are aimed at determining the effectiveness of the B-Series system in reducing unaddressed positive margins compared to standard lumpectomy procedures.
When are the results of the trial expected?
The primary endpoint results from the pivotal trial are expected in Q4-2024.
What is the company's mission?
Perimeter Medical Imaging AI aims to enhance surgical outcomes by developing innovative, high-resolution imaging tools to address significant medical needs in cancer surgery.
